Login to Your Account

Clinic Roundup

Tuesday, November 6, 2012
• Genkyotex SA, of Geneva, said Phase I studies demonstrated safety and tolerability following single and multiple oral doses of GKT137831, a NOX 1 and 4 inhibitor.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription